We created this page for medical staff.
- *Read carefully the package insert before use.
- 1Early diagnosis of renal disease with renal tubular dysfunction.
- 2L-FABP levels in urine show significant elevation in the early stage of diabetic nephropathy (early detection), and increases/decreases along with progression of the stage or treatment (assessment of therapeutic effect). L-FABP is detected in urine at an earlier stage than microalbumin.
- 3Assessment of microcirculatory disorder (ischemia). E.g., L-FABP reflects peritubular blood flow that may occur from renal reperfusion due to kidney transplantation.
- 4Discriminates the presence or absence of the risk of severe Acute Kidney Injury (AKI).
[Diseases associated with abnormal L-FABP values]
Diabetic nephropathy, Chronic Kidney Disease (CKD), Acute Kidney Injury (AKI)
Reference: Guide to Laboratory Tests 2013-2014, Bunkodo Co., Ltd. (revised)
Acute Kidney Injury(AKI)
- 85cardiovascular surgery patients were divided into AKI and non-AKI groups based on the AKIN criteria. Urinary L-FABP and serum CRE were measured chronologically before and after surgery.
- With the conventional AKI diagnosis method which uses serum creatinine as an index, AKI symptoms were confirmed >24 hrs after surgery. However, urine L-FABP increased significantly among the AKI patient group immediately after surgery. This comparison indicates that urinary L-FABP is a useful marker for predicting AKI at an early stage.
- The urinary L-FABP levels of 140 diabetic nephropathy patients were categorized based on their disease stage. The mean and standard deviation values were calculated and compared to those of healthy individuals.
- Urinary L-FABP levels of diabetic nephropathy patients increased with the progress of disease stage. As it showed a significant increase compared to healthy individuals from early stages of nephropathy, it can be said that L-FABP is useful in early diagnosis of diabetic nephropathy.
Monitoring of Kidney Disease
- ARB was administered to diabetic nephropathy patients for 12 months. Urinary albumin level, urinary L-FABP level, and systolic blood pressure were observed to assess the effects of medical treatment.
- Large decrease in urinary albumin level, urinary L-FABP level, and systolic blood pressure were observed after 6 months and 12 months when compared to the start of the treatment. Similar to urinary albumin, urinary L-FABP is effective for the monitoring and assessing the effectiveness of medical treatments, such as antihypertensive therapy, for early-stage diabetic nephropathy.
"NORUDIA" is a trademark or registered trademark of SEKISUI MEDICAL CO., LTD. in Japan and/or other countries.
We prepared this page for medical staff (doctors, dentists, pharmacists, clinical laboratory technicians, nurses, etc.) in Japan to ensure the correct use of our products. You should be aware that the information provided is not intended for overseas medical staff and the general public.